secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-07-05T23:59:59+00:00
Accession:  0001213900-24-059541
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital SPAC signs LOI to combine with Semnur Pharma at up to $2B valuation
--------------------------------------------------------------------------------

- Pre-transaction equity value of Semnur up to $2.0B, subject to third-party fairness opinion adjustment.
- Expected cash on hand at closing up to $40M depending on SPAC share redemptions.
- Combined company to focus on SP-102 (SEMDEXA), a non-opioid epidural gel for sciatica with FDA Fast Track status.
- Scilex Holding (Nasdaq: SCLX) expected to be majority holder of the combined company.
- Parties anticipate seeking SPAC shareholder approval in second half of 2024; no definitive agreement yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024059541/0001213900-24-059541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024059541/ea0208972-8k_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-059541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer